guest ::
| Home > Publications Database > Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. > print |
| Home > Publications Database > Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. > print |
| 001 | 141658 | ||
| 005 | 20240323120021.0 | ||
| 024 | 7 | _ | |a 10.1186/s12888-019-2377-z |2 doi |
| 024 | 7 | _ | |a pmid:31830934 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC6909459 |2 pmc |
| 024 | 7 | _ | |a altmetric:72791893 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-07982 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Timäus, Charles |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. |
| 260 | _ | _ | |a Heidelberg |c 2019 |b Springer |
| 264 | _ | 1 | |3 online |2 Crossref |b Springer Science and Business Media LLC |c 2019-12-12 |
| 264 | _ | 1 | |3 print |2 Crossref |b Springer Science and Business Media LLC |c 2019-12-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1711119038_19996 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The purpose of this study was to assess the pharmacological treatment strategies of inpatients with borderline personality disorder between 2008 and 2012. Additionally, we compared pharmacotherapy during this period to a previous one (1996 to 2004).Charts of 87 patients with the main diagnosis of borderline personality disorder receiving inpatient treatment in the University Medical Center of Goettingen, Germany, between 2008 and 2012 were evaluated retrospectively. For each inpatient treatment, psychotropic drug therapy including admission and discharge medication was documented. We compared the prescription rates of the interval 2008-2012 with the interval 1996-2004.94% of all inpatients of the interval 2008-2012 were treated with at least one psychotropic drug at time of discharge. All classes of psychotropic drugs were applied. We found high prescription rates of naltrexone (35.6%), quetiapine (19.5%), mirtazapine (18.4%), sertraline (12.6%), and escitalopram (11.5%). Compared to 1996-2004, rates of low-potency antipsychotics, tri-/tetracyclic antidepressants and mood stabilizers significantly decreased while usage of naltrexone significantly increased.In inpatient settings, pharmacotherapy is still highly prevalent in the management of BPD. Prescription strategies changed between 1996 and 2012. Quetiapine was preferred, older antidepressants and low-potency antipsychotics were avoided. Opioid antagonists are increasingly used and should be considered for further investigation. |
| 536 | _ | _ | |a 342 - Disease Mechanisms and Model Systems (POF3-342) |0 G:(DE-HGF)POF3-342 |c POF3-342 |f POF III |x 0 |
| 542 | _ | _ | |i 2019-12-01 |2 Crossref |u http://creativecommons.org/licenses/by/4.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Anticonvulsants: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Antidepressive Agents: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Antimanic Agents: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Antipsychotic Agents: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Borderline Personality Disorder: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Borderline Personality Disorder: epidemiology |2 MeSH |
| 650 | _ | 2 | |a Borderline Personality Disorder: psychology |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Germany: epidemiology |2 MeSH |
| 650 | _ | 2 | |a Hospitalization: trends |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Narcotic Antagonists: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Prevalence |2 MeSH |
| 650 | _ | 2 | |a Psychotropic Drugs: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Retrospective Studies |2 MeSH |
| 650 | _ | 2 | |a Time Factors |2 MeSH |
| 650 | _ | 2 | |a Young Adult |2 MeSH |
| 700 | 1 | _ | |a Meiser, Miriam |b 1 |
| 700 | 1 | _ | |a Bandelow, Borwin |b 2 |
| 700 | 1 | _ | |a Engel, Kirsten R |b 3 |
| 700 | 1 | _ | |a Paschke, Anne M |b 4 |
| 700 | 1 | _ | |a Wiltfang, Jens |0 P:(DE-2719)2811317 |b 5 |u dzne |
| 700 | 1 | _ | |a Wedekind, Dirk |b 6 |
| 773 | 1 | 8 | |a 10.1186/s12888-019-2377-z |b : Springer Science and Business Media LLC, 2019-12-01 |n 1 |p 393 |3 journal-article |2 Crossref |t BMC Psychiatry |v 19 |y 2019 |x 1471-244X |
| 773 | _ | _ | |a 10.1186/s12888-019-2377-z |g Vol. 19, no. 1, p. 393 |0 PERI:(DE-600)2050438-X |n 1 |q 19:1<393 |p 393 |t BMC psychiatry |v 19 |y 2019 |x 1471-244X |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/141658/files/DZNE-2020-07982.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/141658/files/DZNE-2020-07982.pdf?subformat=pdfa |
| 856 | 7 | _ | |2 Pubmed Central |u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909459 |
| 909 | C | O | |o oai:pub.dzne.de:141658 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2811317 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-342 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Disease Mechanisms and Model Systems |x 0 |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-09 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-09 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BMC PSYCHIATRY : 2021 |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-02-14T16:20:14Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-02-14T16:20:14Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-09 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-09 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-09 |
| 920 | 1 | _ | |0 I:(DE-2719)1410006 |k AG Wiltfang |l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1410006 |
| 980 | 1 | _ | |a FullTexts |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.4088/JCP.v69n0404 |2 Crossref |o 10.4088/JCP.v69n0404 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1521/pedi.2010.24.4.412 |2 Crossref |o 10.1521/pedi.2010.24.4.412 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1007/s00406-019-00980-8 |2 Crossref |o 10.1007/s00406-019-00980-8 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.comppsych.2008.01.007 |2 Crossref |o 10.1016/j.comppsych.2008.01.007 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1521/pedi.2008.22.4.353 |2 Crossref |o 10.1521/pedi.2008.22.4.353 |
| 999 | C | 5 | |y 2012 |2 Crossref |o JM Stoffers 2012 |
| 999 | C | 5 | |2 Crossref |o |
| 999 | C | 5 | |y 2010 |2 Crossref |o JM Stoffers 2010 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1192/bjp.bp.108.062984 |2 Crossref |o 10.1192/bjp.bp.108.062984 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1007/s40263-017-0425-0 |2 Crossref |o 10.1007/s40263-017-0425-0 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1176/ajp.2006.163.5.827 |2 Crossref |o 10.1176/ajp.2006.163.5.827 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1371/journal.pone.0171592 |2 Crossref |o 10.1371/journal.pone.0171592 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1007/s00115-011-3462-9 |2 Crossref |o 10.1007/s00115-011-3462-9 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1176/ajp.155.12.1733 |2 Crossref |o 10.1176/ajp.155.12.1733 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/YIC.0000000000000021 |2 Crossref |o 10.1097/YIC.0000000000000021 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.euroneuro.2015.03.017 |2 Crossref |o 10.1016/j.euroneuro.2015.03.017 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.4088/JCP.14m09228 |2 Crossref |o 10.4088/JCP.14m09228 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1176/appi.ps.201400055 |2 Crossref |o 10.1176/appi.ps.201400055 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.2174/092986711796504682 |2 Crossref |o 10.2174/092986711796504682 |
| 999 | C | 5 | |y 2010 |2 Crossref |o M Jariani 2010 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1007/s11920-014-0534-0 |2 Crossref |o 10.1007/s11920-014-0534-0 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1176/appi.ajp.2014.13101348 |2 Crossref |o 10.1176/appi.ajp.2014.13101348 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.3109/15622970309167910 |2 Crossref |o 10.3109/15622970309167910 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1176/appi.ajp.2018.17091006 |2 Crossref |o 10.1176/appi.ajp.2018.17091006 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1055/s-2001-15305 |2 Crossref |o 10.1055/s-2001-15305 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1176/ajp.142.1.98 |2 Crossref |o 10.1176/ajp.142.1.98 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1037/a0018095 |2 Crossref |o 10.1037/a0018095 |
| 999 | C | 5 | |y 1996 |2 Crossref |o AS Roth 1996 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.4088/JCP.v58n0106e |2 Crossref |o 10.4088/JCP.v58n0106e |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/00005053-199603000-00011 |2 Crossref |o 10.1097/00005053-199603000-00011 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.3310/hta11060 |2 Crossref |o 10.3310/hta11060 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1176/appi.ajp.2008.08020304 |2 Crossref |o 10.1176/appi.ajp.2008.08020304 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/01.jcp.0000130555.63254.73 |2 Crossref |o 10.1097/01.jcp.0000130555.63254.73 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/01.ALC.0000139704.88862.01 |2 Crossref |o 10.1097/01.ALC.0000139704.88862.01 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1093/alcalc/36.6.544 |2 Crossref |o 10.1093/alcalc/36.6.544 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.4088/JCP.v69n0511 |2 Crossref |o 10.4088/JCP.v69n0511 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1192/bjp.bp.110.078105 |2 Crossref |o 10.1192/bjp.bp.110.078105 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/00004850-199510030-00005 |2 Crossref |o 10.1097/00004850-199510030-00005 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.4088/JCP.v60n0906 |2 Crossref |o 10.4088/JCP.v60n0906 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/YIC.0b013e32834d0e50 |2 Crossref |o 10.1097/YIC.0b013e32834d0e50 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/YIC.0000000000000170 |2 Crossref |o 10.1097/YIC.0000000000000170 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/JCP.0000000000000232 |2 Crossref |o 10.1097/JCP.0000000000000232 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1080/15622970701685224 |2 Crossref |o 10.1080/15622970701685224 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1037/ccp0000275 |2 Crossref |o 10.1037/ccp0000275 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1001/jamapsychiatry.2016.4287 |2 Crossref |o 10.1001/jamapsychiatry.2016.4287 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|